CLOZARIL (clozapine) by Charter Medical is unknown. First approved in 1989.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
CLOZARIL (clozapine) is an oral atypical antipsychotic approved in 1989 for schizophrenia treatment. It works primarily through antagonism of dopamine D2 and serotonin 5-HT2A receptors, with additional activity at adrenergic, cholinergic, and histaminergic receptors. This drug remains a critical option for treatment-resistant schizophrenia despite its safety profile.
Product is in LOE-approaching phase with modest Medicare utilization; expect defensive commercial strategies and potential reallocation of team resources.
unknown. However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D 2 ) and the serotonin type 2A (5-HT 2A ) receptors. CLOZARIL also acts as an antagonist at adrenergic, cholinergic, histaminergic and other…
Atypical Antipsychotic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia
Biomarkers in Clozapine-responding Schizophrenia
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia
Augmenting Clozapine With Sertindole - SERCLOZ
Worked on CLOZARIL at Charter Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moOnly 2 linked jobs currently available, primarily in IT and business architecture rather than traditional pharma commercial roles, reflecting the product's mature status. Career progression on CLOZARIL will focus on operational efficiency and digital transformation rather than growth commercialization.
2 open roles linked to this drug